FDA ApprovalYutrepia has received full FDA approval in both PH-ILD and PAH, positioning it strongly in the market.
Market PotentialYutrepia is expected to have peak sales of approximately $1 billion, with a significant portion in the ILD market segment.
Product LaunchLiquidia Technologies plans to launch Yutrepia into two large, orphan markets, which is expected to drive significant sales.